GET THE APP

Does availability of higher antibiotics will help in reducing mor | 28159
Journal of Pharmaceutical Care & Health Systems

Journal of Pharmaceutical Care & Health Systems
Open Access

ISSN: 2376-0419

Does availability of higher antibiotics will help in reducing mortality in VAP?


Global Pharma Summit

August 10-12, 2015 Philadelphia, USA

Lekharaj Hemraj Ghotekar and Sumedh Dhuldhule

ScientificTracks Abstracts-Workshop: J Pharma Care Health Sys

Abstract :

We conducted a study to find out the microbes causing and the antibiotics sensitivity in sixty adult patients of Ventilator Associated Pneumonia in a tertiary care hospital. CDC definition of VAP was followed for the diagnosis. Endotracheal aspirate was obtained immediately following clinical suspicion of pneumonia and was subjected for quantitative qualitative analysis. Acinetobacter baumannii was found to be associated with early and late onset pneumonia and resistant to most of the first line antibiotics. This may be due to frequent use of these antibiotics in many patients developing early-onset VAP. Carbapenams and Colistin was found to be having higher sensitivity as an antimicrobial agent than conventional. Amongst the microbes higher incidence of multidrug resistant was noted with Acinetobacter. Overall mortality of VAP was 66.66% and the length of ICU stay was cases were observed to be 9.44±3.62 ranging from minimum 5 to maximum of 21 days. Duration of mechanical ventilation was 8.28±3.62 ranging from 4 to 21 days. The overall incidence and mortality rate among late onset group pneumonia was higher 81.82%, much higher than early onset group 25%. The length of ICU stay for early onset pneumonia was 8.81±2.71 (ranging from 6-16) and total duration of mechanical ventilation was 8.56±3.43 ranging from 4 to 21 days. Similarly, statistically significant mortality rate was found in late onset VAP compared to early VAP. There is constant need of higher antibiotics and strict following of guidelines for usage of antibiotics in ICU set up to prevent development and mortality associated with VAP.

Biography :

Lekharaj Hemraj Ghotekar has completed his MD from Nagpur University. He is a Professor of Medicine in a Premier Medical College of Delhi, India. He has published more than 29 papers in reputed indexed national and international journals and is a fellow and member of many national and international medical societies and associations.

Top